ORLANDO, FL (UroToday) - Highlights of the advance prostate cancer session included; effectiveness of salvage radiation therapy for a rising PSA after radical prostatectomy, role of an extended lymph node dissection, dutesteride for rising PSA, use of anti-PSMA monoclonal antibodies for hormone-refractory prostate cancer, and long-term side effects of androgen deprivation.

Abstract 522 evaluated men with a rising PSA after radical prostatectomy. External beam radiation was able to provide long0term biochemical-free survival in 83%, 50%, and 7% of patients with positive surgical margins, seminal vesicle invasion, and positive lymph nodes, respectively.

Abstract 528 showed that an extended lymph node dissection with long-term androgen deprivation resulted in a 53% 10-year disease-free survival rate.

Abstracts 514 and 515 showed that in patients with a rising PSA after treatment, Dutesteride could decrease the PSA level by 50% in 42% of patients with minimal side effects.

Abstract 724 was a phase I trial of 177-Lutetium, which is an anti-PSMA monoclonal antibody. The agent was well tolerated and showed tumor regression in a significant number of patients with hormone-refractory prostate cancer.

Finally, Abstract 531 evaluated 6,437 men who had received androgen deprivation therapy for more than 1.5 years. Dementia and COPD were the main non-GU side effects associated with long-term androgen deprivation.

Presented by Ziya Kirkall, MD, at the Annual Meeting of the American Urological Association (AUA) - May 17 - 22, 2008. Orange County Convention Center - Orlando, Florida, USA.

Reported by UroToday Contributing Editor David P. Wood, MD

UroToday - the only urology website with original content global urology key opinion leaders actively engaged in clinical practice.

To access the latest urology news releases from UroToday, go to: www.urotoday

Copyright © 2008 - UroToday